LAGUNA HILLS, Calif., Sept. 30 /PRNewswire/ -- Minnow Medical, Inc., a developer of a novel platform technology employing radiofrequency thermoplasty for the treatment of in-stent restenosis and other peripheral vascular conditions, announced today that veteran medical technology executive Raymond W. Cohen has been named chief executive officer and a member of the board of directors.
Cohen, 51, has more than 25 years of leadership and entrepreneurial experience in health care. For the past four years, he has been the CEO of CardioPolymers, Inc., a privately-held developer of novel biotherapeutics for the treatment of congestive heart failure, which recently merged with LoneStar Heart, Inc., where Cohen remains a member of the board of directors. In 2008, during his tenure at CardioPolymers, Inc., Cohen was named by AeA (now TechAmerica) as the Private Company Life Science CEO of the Year.
Cohen serves as a member of the board of directors of publicly-traded Cardiogenesis, Inc., a manufacturer of transmyocardial revascularization lasers; publicly-traded BioLife Solutions, Inc., a manufacturer of cryopreservation products used for human cell and tissue preservation; and Syncroness, Inc., a privately-held contract engineering and product development firm; and also serves as an advisor to Fjord Ventures, LLC, a life science incubator.
Previously, Cohen served as chairman and chief executive officer of publicly-held Cardiac Science, Inc., a leading U.S. manufacturer of life-saving automatic public-access defibrillators. In 2004, Cardiac Science was ranked the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. During his tenure, Cohen was named Entrepreneur of the Year in 2002 by the Orange County Business Journal.
Cohen is a member of a number of local Southern California organizations, notably the Forum of Corporate Directors and OCTANe, where he is a member of the Biomedical Leaders
|SOURCE Minnow Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved